| Followers | 52 |
| Posts | 14331 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Monday, July 24, 2023 6:42:12 PM
Assume this is no reason to lie, Raf apparently got a reply from Amarin IR, while not explaining the reason for the Mitigate termination, said that it was not related to safety, efficacy or quality concerns.
"investor.relations@amarincorp.com
to Me & 1 more
Today, 1:37 PM
1h MITIGATE was an Investigator Initiated Trial conducted at Kaiser Permanente Northern California that studied
Amarin's product VASCEPA/VAZKEPA (icosapent ethyl). Investigator Initiated Trials, or ITs, are run by the
investigators who initiate them. Recently Amarin was notified by Kaiser Permanente that the trial had been terminated prior to analysis of the study data. The study was not terminated or stopped due to any safety, efficacy or quality concerns
related to VASCEPA/VAZKEPA (icosapent ethyl). Amarin will have no further comment on the MITIGATE study or the circumstances surrounding the study's
termination.
Thank you,
Amarin IR"
Further I noticed that today (I believe) Raf was posting on ST that "Mitigate was stolen" from us and that he believes it was fraud. Not really sure I understand exactly what he is implying. If anyone can elucidate, it would be appreciated.
"investor.relations@amarincorp.com
to Me & 1 more
Today, 1:37 PM
1h MITIGATE was an Investigator Initiated Trial conducted at Kaiser Permanente Northern California that studied
Amarin's product VASCEPA/VAZKEPA (icosapent ethyl). Investigator Initiated Trials, or ITs, are run by the
investigators who initiate them. Recently Amarin was notified by Kaiser Permanente that the trial had been terminated prior to analysis of the study data. The study was not terminated or stopped due to any safety, efficacy or quality concerns
related to VASCEPA/VAZKEPA (icosapent ethyl). Amarin will have no further comment on the MITIGATE study or the circumstances surrounding the study's
termination.
Thank you,
Amarin IR"
Further I noticed that today (I believe) Raf was posting on ST that "Mitigate was stolen" from us and that he believes it was fraud. Not really sure I understand exactly what he is implying. If anyone can elucidate, it would be appreciated.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
